- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05162196
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
2022년 4월 28일 업데이트: Conghua Xie,MD,PhD, Wuhan University
Radiotherapy Combined With Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer (CREATE): A Open-label, Single-arm, Phase II Study
This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).
연구 개요
연구 유형
중재적
등록 (예상)
57
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Conghua Xie, MD,PhD
- 전화번호: 0086-27-67812607
- 이메일: chxie_65@hotmail.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Histologically or cytologically confirmed small cell lung cancer.
- Age ≥ 18 years.
- Previously received 1-2 lines of treatment (including 1 systemic platinum-containing treatment), and responded to the first platinum-containing treatment (response is defined as CR, PR or SD).
- At least 1 measurable target lesion based on RECIST 1.1.
- Allow previous anti-PD-L1 antibody treatment, enrolled patients ≤ 30% of the total enrolled number.
- Life expectancy ≥ 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-2.
- Adequate hematologic function, hepatic function and renal function
- Female who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must be willing to use an adequate method of contraception.
- Male subjects of childbearing potential must agree to use an adequate method of contraception (failure rate < 1% per year) - Contraception, starting with the first dose of study therapy through 6 months after the last dose of study therapy.
- . Toxic side effect to any previous chemotherapy has returned to ≤ CTCAE Grade 1 or baseline, or except sensory neuropathy or hair loss with stable symptoms ≤ CTCAE Grade 2.
Exclusion Criteria:
- People who are known to be allergic to Niraparib or to active or inactive ingredients of drugs with similar chemical structure to Niraparib.
- People who are known to be allergic to Toripalimab or to active or inactive ingredients of drugs with similar chemical structure to Toripalimab.
- Symptomatic and uncontrolled cerebral or leptomeningeal metastasis. No imaging scan is required to confirm no brain metastases; subjects with spinal cord compression may be considered for inclusion if they have received targeted treatment and evidence of clinical stability of the disease for at least 28 days (patients with controlled CNS metastases must have received treatment such as radiotherapy or chemotherapy at least one month before entering the study; subjects should not develop new symptoms related to central nervous system lesions or symptoms indicating disease progression, and subjects either take stable doses of hormones or do not need to take hormones).
- Chemotherapy or major surgery was performed within 3 weeks prior to the study or any surgical effect that has not been recovered after surgery.
- Radiotherapy for target lesions within 4 weeks of initiating study drugs, or palliative radiotherapy for >20% bone marrow within 1 week prior to enrollment.
- Patients with high risk of massive hemoptysis (such as uncured bronchiectasis, pulmonary tuberculosis).
- Malignancies other than small cell lung cancer within 5 years prior to enrollment (except for radically treated cervical cancer in situ, basal cell carcinoma and superficial bladder tumor).
- Patients with previously or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Severe or uncontrolled conditions or diseases, including but not limited to:
- Uncontrollable nausea and vomiting, inability to swallow study drugs, or any gastrointestinal disease that could affect drug absorption or metabolism.
- Active virus infections such as human immunodeficiency virus (HIV) (positive HIV antibody), hepatitis B virus (HBV; positive HBsAg-positive status and HBV-DNA ≥10^3 copy number/mL or ≥500 IU/mL), and hepatitis C virus (HCV; positive anti-HCV antibody and/or positive HCV RNA in combination with clinical judgment).
- Uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or mental disease impairing the participant's ability to give informed consent.
- Known diagnosis of immunodeficiency (except for splenectomy) or other conditions that might predispose participants to a high risk of toxicity, as judged by the investigator.
- Need to use any type of corticosteroids for systemic treatment within 14 days of study medication (>10mg/day prednisone) or other immunosuppressive drugs; in the absence of active autoimmune diseases, inhaled or topical steroids and Adrenal replacement dose (≤10mg/day prednisone); Allow patients to use topical, intraocular, intra-articular, intranasal and inhaled corticosteroids (small systemic absorption); allow physiological alternative doses of systemic corticosteroids (≤10mg/day prednisone); for prevention (such as contrast agents) Allergy) or short-term corticosteroid therapy for non-autoimmune diseases (such as delayed hypersensitivity caused by contact allergens) is allowed.
History of bleeding tendency and thrombosis:
- Any bleeding events with CTCAE level 2 occurred within 3 months before screening, or with CTCAE level 3 and above within 6 months before screening
- A history of gastrointestinal hemorrhage or a clear tendency of gastrointestinal hemorrhage within 6 months before screening. For example: esophageal varices with bleeding risk, local active ulcer lesions, or fecal occult blood + + or above
- With active bleeding or coagulation abnormalities, bleeding tendency, or receiving thrombolytic or anticoagulation therapy
- Subjects need anticoagulant therapy with warfarin or heparin
- Subjects will require long-term antiplatelet therapy (e.g., aspirin, clopidogrel)
- Thrombotic or embolic event within the past 6 months, e.g., cerebrovascular accident (including transient ischemic attack), and pulmonary embolism.
Serious cardiovascular history:
- NYHA (New York Heart Association) grade 3 and 4 congestive heart failure
- Unstable angina or newly diagnosed angina or myocardial infarction within 12 months before screening
- Arrhythmias requiring therapeutic intervention (subjects taking β-blockers or digoxin may be enrolled)
- ≥ CTCAE Grade 2 valvular heart disease
- Poorly controlled hypertension (SBP > 150 mmHg or DBP > 100 mmHg).
Other laboratory abnormalities:
- Hyponatremia (sodium <130 mmol/L); baseline serum potassium <3.5 mmol/L (potassium supplements can be used to restore serum potassium to above level before entering the study).
- Abnormal thyroid function which cannot be maintained within the normal range with drugs.
- Any previous or current disease, treatment or laboratory abnormality that may interfere with the results of the study, affect the subject's participation in the whole process of the research, or the researcher believes that the subject is not suitable for participating in this research; the subjects should not receive platelet or red cell transfusion within 4 weeks prior to the start of treatment with the study drug.
- Subjects who are pregnant or breast-feeding or expect to become pregnant during the study treatment period.
- Corrected QT interval (QTc)>450 milliseconds; if the subject has a prolonged QTc interval, but the investigator evaluates that the cause of the prolongation is a cardiac pacemaker (without other cardiac abnormalities), it is necessary to discuss with the investigator to determine whether the subject is suitable for inclusion in the study.
- Previous treatment with any PARP inhibitors.
- Previous treatment with any anti-PD-1 inhibitors.
- Subjects are participating in other clinical studies or it is less than 1 month from the end of the previous clinical study.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: SBRT combined with Niraparib and Toripalimab
Induction therapy (cyc1: D1-D28): Niraparib 200mg QD + SBRT 8Gy✖️3 QD, D4-D6 + Toripalimab 240mg iv drip D7 Maintenance (cyc2+): Niraparib 200mg QD, D1-D21 + Toripalimab 240mg iv drip D1, until disease progression or intolerable toxicity |
토리팔리맙 240mg, ivgtt, d1, q3w.
24Gy/3F
200mg qd
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
ORR (Objective response rate)
기간: Approximately 2 years
|
Objective response rate (ORR) evaluated by investigators and BIRC based on RECIST1.1
|
Approximately 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
무진행생존율(PFS) 비율
기간: 약 1년
|
6개월(선발자 및 BICR) 및 1년 PFS 요율
|
약 1년
|
DOR (Duration of Response)
기간: Approximately 2 years
|
Duration of response (DOR) evaluated by investigators and BIRC based on RECIST1.1
|
Approximately 2 years
|
DCR (Disease of Response)
기간: Approximately 2 years
|
Disease control rate (DCR) evaluated by investigators and BIRC based on RECIST1.1
|
Approximately 2 years
|
PFS (Progression Free Survival)
기간: Approximately 2 years
|
Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1)
|
Approximately 2 years
|
Overall suvival (OS)
기간: Approximately 2 years
|
Overall suvival (OS)
|
Approximately 2 years
|
OS (Overall Survival) rate
기간: Approximately 1 years
|
OS rates at 1 years
|
Approximately 1 years
|
Intrathoracic and extrathoracic recurrence rate
기간: Approximately 2 years
|
Approximately 2 years
|
|
The incidence of adverse events (AEs) as a measure of safety
기간: Approximately 2 years
|
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product.
Safety and tolerance evaluated by incidence, severity and outcomes of AEs (according to NCI-CTCAE 5.0)
|
Approximately 2 years
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (예상)
2022년 6월 1일
기본 완료 (예상)
2024년 6월 1일
연구 완료 (예상)
2024년 12월 1일
연구 등록 날짜
최초 제출
2021년 12월 4일
QC 기준을 충족하는 최초 제출
2021년 12월 4일
처음 게시됨 (실제)
2021년 12월 17일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2022년 5월 2일
QC 기준을 충족하는 마지막 업데이트 제출
2022년 4월 28일
마지막으로 확인됨
2022년 4월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CREATE
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
토리팔리맙에 대한 임상 시험
-
Shanghai Junshi Bioscience Co., Ltd.완전한
-
Shanghai Junshi Bioscience Co., Ltd.모집하지 않고 적극적으로
-
Shanghai Junshi Bioscience Co., Ltd.모집하지 않고 적극적으로1차 질환: 절제 불가능 또는 전이성 신장 세포 암종 연구 초점: RECIST 1.1에 따라 IRC에서 평가한 PFS중국
-
The First Hospital of Jilin University모병절제 가능한 위암을 가진 PD-L1 양성 국소 진행 환자중국